Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Name: Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
Published: 2019
License: Public Domain

Merck Sharp & Dohme LLC · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

advanced/metastatic solid tumors, programmed cell death 1 (pd-1, pd1), programmed cell death ligand 1 (pd-l1, pdl1), interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Related documents